Key Takeaways
- A 2025 global scoping review in Neurological Sciences found that telemedicine documentation practices in neurology and telestroke vary widely across countries, with no consistent standard for what must be recorded during a virtual neurological encounter.
- A 2025 analysis in Psychiatric Services found that direct-to-consumer telehealth platforms dispensing off-label ketamine often lack the documentation infrastructure needed to establish informed consent, track adverse events, or assign clear clinical liability.
- A 2025 study in Sexual Medicine found that unapproved peptides are being prescribed through online platforms in states with looser oversight, with little evidence of standardized clinical documentation or follow-up protocols.
- The American College of Physicians’ 2025 position paper in Annals of Internal Medicine called for uniform telehealth documentation requirements across state lines, citing fragmented records as a patient safety concern.
- A global review in the Journal of Telemedicine and Telecare found that telemedicine-enabled buprenorphine programs in multiple countries operate without agreed documentation benchmarks, complicating audits and quality improvement efforts.
Why is telehealth documentation a patient safety problem right now?
Telehealth documentation is a patient safety problem right now because clinicians across telehealth platforms operate without consistent standards for what gets recorded, how completely, or whether that record reaches the patient’s other providers. A 2025 global scoping review published in a neurology and telestroke context found that telemedicine documentation practices vary dramatically across settings, with no agreed framework governing what a telehealth encounter record must contain.
That inconsistency has real consequences for patients.
When a telehealth provider prescribes a controlled substance or an off-label medication and the visit note is thin, missing, or siloed inside a proprietary platform, the patient’s primary care doctor or emergency physician has no reliable record to work from. A 2025 analysis of direct-to-consumer ketamine prescribing identified this gap explicitly, finding that liability risks and ethical responsibilities in off-label telehealth prescribing compound when documentation fails to capture the clinical reasoning behind a prescription—leaving both the patient and any subsequent provider without a clear picture of what was decided and why.
The American College of Physicians made this concrete in a 2025 position paper: ACP’s telemedicine policy calls for documentation standards in telehealth to match those required in in-person care, a standard the organization acknowledged is not currently being met across the sector.
Three specific documentation failures show up repeatedly in the evidence:
- Incomplete visit notes. Telehealth platforms—especially direct-to-consumer services—frequently generate abbreviated records that omit physical exam limitations, the basis for diagnosis, or the rationale for prescribing a specific drug at a specific dose.
- No care coordination pathway. A global review of telemedicine for opioid use disorder found that record-sharing between telehealth prescribers and community pharmacists or primary care providers is inconsistent, meaning patients on buprenorphine or other controlled medications may be managed in an information vacuum.
- Regulatory gaps enabling the problem. A 2025 study on telepharmacy in Indonesia found that pharmacists operating without regulatory support had no enforceable documentation requirements to rely on—a dynamic that mirrors what consumer-facing telehealth platforms face in U.S. states with weak or absent telehealth-specific rules.
For patients, the practical risk is this: if something goes wrong—a drug interaction, an adverse reaction, a missed diagnosis—the documentation trail that any investigating clinician or insurer would need may simply not exist in a usable form. Patients using telehealth services should ask, before the visit ends, for a complete written visit summary and confirm whether that record will be shared with their existing providers.
This section presents general health system information for consumer awareness purposes and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare professional for guidance specific to your situation.
What do telestroke and neurology records actually look like across countries?
Telestroke and neurology telehealth documentation records vary dramatically across countries — in format, completeness, and legal enforceability — and patients often have no reliable way to know what standard applies to the provider treating them. A 2025 global scoping review examined telemedicine documentation in neurology and telestroke programs worldwide and found no consistent international standard governing what clinicians must record during a remote neurological encounter.
The gap matters. The same review identified wide variation in how providers document consent, clinical findings, and follow-up plans across health systems. Some programs produced structured records comparable to in-person neurology notes. Others generated minimal logs — essentially a timestamp and a prescription — with no documented neurological examination findings at all.
The review surfaced several patterns:
- High-income countries with established telestroke networks (the United States, Australia, parts of Western Europe) tended to produce more complete records, partly because reimbursement systems required them.
- Low- and middle-income country programs frequently operated without formal documentation protocols, meaning records existed at the discretion of individual clinicians rather than institutional policy.
- Consent documentation was the single most inconsistently recorded element across all settings reviewed.
The American College of Physicians has called for telemedicine documentation standards that match in-person care requirements, arguing that incomplete records create both patient safety risks and liability gaps. That position paper was published in 2025 and reflects ongoing — not resolved — policy debate.
For patients, the practical takeaway is blunt: before a telestroke or remote neurology consultation, ask the provider directly what records you will receive, in what format, and how long they are retained. If a telehealth company cannot answer those questions clearly, that tells you something about how seriously it treats the encounter as actual medical care.
This content presents general health information for educational purposes only and is not medical advice, diagnosis, or a treatment recommendation. Consult a qualified healthcare professional for guidance specific to your situation.
How does off-label ketamine prescribing via telehealth expose documentation gaps?
Off-label ketamine prescribing via telehealth exposes documentation gaps because no uniform federal standard requires these platforms to record the clinical reasoning, patient history review, or follow-up protocols that justify prescribing a controlled substance outside its FDA-approved indications. A 2025 paper published in PMID 42159594 states directly that direct-to-consumer telehealth ketamine companies operate in a space where liability frameworks are unclear and ethical documentation obligations remain largely unenforced.
The gap is structural. When a patient books a ketamine consultation through a telehealth app, the prescribing clinician may spend as little as 30–45 minutes reviewing intake forms the patient filled out themselves—no physical exam, no coordination with the patient’s existing psychiatrist or primary care physician. The PMID 42159594 paper identifies this absence of integrated care records as a core liability risk that falls on patients when adverse events occur, because the documentation trail needed to reconstruct clinical decision-making simply does not exist.
Telemedicine documentation standards vary sharply by specialty and jurisdiction. A global scoping review on telemedicine documentation found that even in well-resourced neurology and telestroke programs, documentation practices are inconsistent across platforms and countries, with no consensus on what a complete telehealth record must contain. Ketamine platforms, which operate in a far less regulated corner of telehealth, face even weaker accountability.
The American College of Physicians has called for clearer telemedicine policy, arguing in its 2024 position paper that prescribing via telehealth should meet the same standard of care as in-person prescribing—including documentation of medical necessity. Most off-label ketamine platforms do not publicly demonstrate they meet that bar.
For patients, the practical consequences are concrete:
- No paper trail for adverse events. If a patient experiences a dissociative episode or cardiovascular complication, sparse records make it difficult for emergency providers to understand what was prescribed, at what dose, and why.
- No continuity mechanism. Platforms that prescribe but do not coordinate with outpatient mental health providers leave gaps in longitudinal care records that other clinicians cannot fill.
- No audit trail for regulators. State medical boards investigating a complaint need documentation of clinical reasoning. When that documentation is thin or templated, enforcement stalls.
The PMID 42159594 authors argue that companies marketing ketamine as a mental health solution carry an ethical responsibility to maintain records that would survive regulatory scrutiny. Right now, many do not.
This section presents general information for consumer awareness and is not medical advice. Consult a qualified healthcare professional before making any decisions about your care.
Are peptide and sexual medicine platforms keeping adequate clinical records?
Telehealth documentation on peptide and sexual medicine platforms is inconsistent, often thin, and in some cases structured more around sales conversion than clinical safety. Patients should not assume that a brief intake questionnaire or a video call constitutes a complete medical record.
The American College of Physicians ACP position paper states that telemedicine encounters carry the same documentation obligations as in-person visits — meaning providers must record a full history, clinical reasoning, and follow-up plan. Many direct-to-consumer platforms dispensing peptides or sexual health medications do not meet that bar. A scoping review on telemedicine documentation found wide variation in what gets recorded across telehealth encounters, with gaps in structured data capture and follow-up documentation appearing across multiple care settings. That review focused on neurology and telestroke, but the documentation architecture — or lack of it — applies across specialties.
Peptide prescribing carries specific risks. A 2025 analysis of peptide availability in sexual medicine found that access to these compounds varies sharply by state and that regulatory oversight of prescribing practices remains fragmented. No single authority audits whether platforms are keeping records adequate enough to catch adverse events, drug interactions, or patterns of misuse across their patient populations.
Research on off-label ketamine via direct-to-consumer telehealth shows that thin documentation creates concrete legal exposure for prescribers and leaves patients without a paper trail if something goes wrong. The same dynamic applies to peptide and sexual medicine platforms: when a patient experiences a side effect months after a prescription, an incomplete record makes it nearly impossible to reconstruct what the provider knew, when they knew it, and what they told the patient.
What patients can do right now:
- Request a copy of your visit notes after any telehealth encounter. A legitimate provider can produce them. Silence or vague responses are a warning sign.
- Check whether the platform assigns you a named, licensed clinician — not just a rotating pool of prescribers with no continuity of care.
- Ask how your records are stored and who can access them if the platform closes or changes ownership, a real risk in a market where many peptide telehealth companies are venture-backed startups with no long-term track record.
The ACP position paper explicitly calls for telehealth providers to maintain care continuity and coordinate with primary care physicians. Most peptide and sexual medicine platforms do neither — and no federal rule currently forces them to.
This section presents general information for educational purposes and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare professional for guidance specific to your situation.
What happens to buprenorphine and opioid care records in telemedicine programs?
Buprenorphine and opioid care records in telemedicine programs face serious documentation gaps—gaps that follow patients across providers, complicate continuity of care, and create legal exposure for both clinicians and the platforms prescribing controlled substances remotely. This is not hypothetical. It is a structural problem baked into how many direct-to-consumer telehealth companies currently operate.
A global scoping review on telemedicine documentation found that documentation standards across telehealth settings vary dramatically, with no consistent international framework governing what must be recorded, retained, or shared when a clinician treats a patient remotely. For buprenorphine—a Schedule III controlled substance used to treat opioid use disorder—that inconsistency carries real consequences.
Here is what the evidence shows about how records are handled, and where the system breaks down:
Prescription monitoring programs (PDMPs): Clinicians prescribing buprenorphine via telehealth are generally required to report to state PDMPs. A global review of telemedicine-based opioid use disorder treatment found that regulatory requirements, reporting practices, and enforcement vary sharply by country and by U.S. state, leaving meaningful gaps in cross-jurisdictional visibility.
Platform-controlled records: Many telehealth companies store clinical records in proprietary systems. When a company closes, pivots its business model, or gets acquired, patients lose access to their own treatment history. The American College of Physicians position paper on telemedicine calls for telehealth platforms to meet the same documentation and records-transfer standards as brick-and-mortar practices—a standard many commercial platforms do not currently meet.
Continuity of care breakdowns: A retrospective cohort study on buprenorphine patients and health services usage found that patients receiving buprenorphine for opioid use disorder have distinct health service patterns requiring coordinated, longitudinal records. When telehealth documentation is fragmented or siloed, the next treating clinician—whether in an emergency department or a new prescriber—works blind.
Liability and ethics in remote prescribing: Research on direct-to-consumer telehealth and off-label prescribing identifies documentation failures as a core liability risk, noting that inadequate records make it nearly impossible to demonstrate that informed consent was obtained or that clinical decision-making met the standard of care.
Patients should ask any telehealth buprenorphine provider, in writing, exactly where their records are stored, how long they are retained, and what happens to those records if the company stops operating. A provider that cannot answer those questions clearly is a provider worth reconsidering.
This content is general health information for educational purposes only and is not medical advice, diagnosis, or treatment. Consult a qualified healthcare professional about your specific situation.
What reforms are physicians and researchers calling for?
Physicians and researchers are calling for telehealth reforms that address documentation standards, prescribing guardrails, and consistent state-level regulation — gaps that currently leave patients exposed to uneven care quality and unclear legal protections. The calls are specific, and they come with evidence.
The American College of Physicians laid out a detailed position in 2025, arguing that telehealth policy must require the same standard of care online as in person, that payers must cover telehealth services equitably, and that interstate licensing barriers need structural solutions so patients aren’t cut off from care when they cross state lines. The ACP position paper also calls on platforms to disclose conflicts of interest — a pointed concern given how many direct-to-consumer telehealth companies profit from the prescriptions their own affiliated clinicians write.
Documentation is a specific flashpoint. A global scoping review of telemedicine in neurology found wide variation in what gets recorded during virtual visits, with no consistent international standard governing what a telehealth encounter must document. The neurology scoping review recommends standardized documentation frameworks so that records are complete enough to support continuity of care and legal accountability.
Researchers studying off-label ketamine prescribing through direct-to-consumer platforms identified sharper demands:
- Platforms must conduct thorough psychiatric screening before prescribing, not after a patient completes a brief online questionnaire.
- Clinicians need clear liability guidance, because current law leaves prescribers in ambiguous territory when a patient is harmed by a drug dispensed without an in-person evaluation.
- Federal regulators should define what constitutes an adequate telehealth prescribing encounter for controlled and high-risk substances.
The ketamine liability analysis frames this as an ethical failure, not just a regulatory gap — platforms marketing ketamine directly to consumers are outpacing the clinical safeguards that would exist in any brick-and-mortar setting.
For opioid use disorder treatment, researchers studying telemedicine-enabled buprenorphine programs found that global practices vary enormously, with some countries requiring supervised dispensing and others allowing fully remote prescribing with no pharmacy check-ins. The global MOUD perspectives study recommends that countries adopt minimum standards for patient monitoring and pharmacist involvement — a call that applies directly to U.S. telehealth platforms dispensing buprenorphine without coordinating with local pharmacies.
State-level peptide prescribing presents a parallel problem. A 2025 study found that peptide availability through telehealth varies dramatically by state, driven by inconsistent compounding pharmacy rules and absent federal oversight. The peptide availability study recommends that federal agencies clarify which peptides require in-person evaluation and which compounded formulations meet safety standards — clarity that patients currently cannot get from a telehealth platform’s marketing page.
This section presents general health policy information for educational purposes and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare professional for guidance specific to your situation.
FAQ
What is telehealth documentation and why does it matter?
Telehealth documentation refers to the clinical records created during a virtual care encounter—notes, consent forms, prescribing rationale, and follow-up plans. Incomplete or inconsistent records make it harder for other providers to continue care safely and create legal liability gaps when things go wrong.
Which clinical areas have the worst telehealth documentation problems?
Peer-reviewed research published in 2025 flags neurology, psychiatry, addiction medicine, and sexual medicine as areas with particularly inconsistent records. A global scoping review in Neurological Sciences and a Psychiatric Services analysis of ketamine prescribing both found documentation practices that vary dramatically by platform and country.
Is off-label ketamine prescribing through telehealth apps documented properly?
According to a 2025 analysis in Psychiatric Services, many direct-to-consumer telehealth platforms dispensing off-label ketamine lack the documentation infrastructure to adequately capture informed consent or adverse events. The authors identified this as both an ethical and a liability problem.
Do online peptide prescribers in sexual medicine keep clinical records?
A 2025 study in Sexual Medicine found that unapproved peptides are available through online platforms in states with minimal oversight, and there is little evidence of standardized clinical documentation or structured follow-up. Access varied significantly by state regulatory environment.
What did the American College of Physicians say about telehealth documentation standards?
In a 2025 position paper published in Annals of Internal Medicine, the American College of Physicians called for uniform telehealth documentation requirements that apply consistently across state lines. The organization cited fragmented records as a direct threat to care continuity and patient safety.
How does poor documentation affect buprenorphine treatment delivered by telemedicine?
A global review in the Journal of Telemedicine and Telecare found that telemedicine-enabled buprenorphine programs across multiple countries operate without agreed documentation benchmarks. That absence makes it difficult to audit outcomes, identify prescribing errors, or hold programs accountable.
Are telepharmacy services facing the same documentation gaps?
A 2025 study in the Journal of Epidemiology and Global Health examined telepharmacy in Indonesia and found pharmacists operating without regulatory frameworks that specify what records must be kept. Without those requirements, there is no consistent baseline for what a telepharmacy encounter should document.
What can patients do to protect themselves given these telehealth documentation gaps?
Patients should ask any telehealth provider for a written summary of the visit, the clinical rationale for any prescription, and a clear plan for follow-up. Consulting a licensed healthcare professional in person—especially before starting a new medication—remains the most reliable safeguard. This article is not medical advice.
This article is for general information and is not medical, legal, or financial advice. Telehealth services, prescriptions, and insurance coverage vary by state and provider — verify a provider’s licensing and consult a qualified professional before making care decisions.